RANINasdaqPharmaceutical PreparationsFiscal year ends December 31
Rani Therapeutics Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.65+0.01 (+1.51%)
Close on Oct 19, 2026
- Market cap
- $121.72M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.9897 (−60.35%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Rani Therapeutics Holdings, Inc. grew revenue 306.4% to $4.88M over the twelve months to Jun 30, 2026. Free cash flow was -$20.34M.
Revenue
$4.88M
+306.4% vs. a year earlier
Operating income
-$32.96M
TTM Q2 2026
Free cash flow
-$20.34M
TTM Q2 2026
EPS, diluted
-$0.45
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $121.72M
- P/E ratio
- –
- Price to sales
- 24.96
- Price to book
- 3.10
- Dividend yield
- –
- Free cash flow yield
- -16.71%
Fundamentals
- Revenue
- $4.88M
- Net income
- -$30.14M
- EPS, diluted
- -$0.45
- Free cash flow
- -$20.34M
- Book value per share
- $0.21
- Diluted shares
- 187M
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
$4.88M+306.4% YoY
Operating income
-$32.96M
Net income
-$30.14M
EPS, diluted
–
Free cash flow
-$20.34M
Reported periodTrailing twelve months